Navigation Links
Response Biomedical Corporation Reports 2007 Financial Results
Date:3/31/2008

nal capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; changing facility costs and other risks relating to our facilities expansion plans; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; fluctuations in interest rates and foreign exchange rates; seasonality including government budget cycles; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 40-F in the U.S.) and other filings with Canadian and Uni
'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Invictus ... a prestigious Illinois university for a second innovative ... (NICUs) more conducive to newborn infants’ cognitive development. ... three NICU problems we have identified through extensive ... professionals,” said George Hutchinson, Invictus Medical’s Chief Technology ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... owner of SunGrubbies.com. “Doesn’t every mother want to look younger ... sun protection is the first line of defense. ... spots that are the evidence of too much time spent ... not the only reason to cover up. The dangers ...
(Date:4/20/2015)... 20, 2015 Heritage Woods of Centralia, ... Open House and Dine-and-Dash Spaghetti Dinner from 4 p.m. ... which is located in Centralia, Illinois, houses senior living ... low-income adults 55 and older. , Guests are invited ... supportive living options for seniors. After the tours, they ...
(Date:4/20/2015)... 2015 Using Quality by Design to ... and Improve Compliance , **FDAnews Webinar**, May 7, 2015 ... , The life sciences industries are going through ... more with less. Mergers, acquisitions, the patent cliff ... ways to speed up production while still maintaining quality ...
(Date:4/20/2015)... Reality show stars, food, fashion and fun ... annual Michigan International Women’s Show, April 30 - May ... lots to see and do from enjoying a makeover ... gifts,” said Beth Anderson, executive show manager of Southern ... appearances from Randy Fenoli of ‘Say Yes to the ...
Breaking Medicine News(10 mins):Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3
... Wound Management,Technologies, Inc., (OTC Bulletin Board: WNDM), announced ... and for 2009. "The company,has been focused on bringing ... 3 quarters of the year to position CellerateRx(TM) as ... We have been working,with several major medical groups, physicians ...
... There is little doubt that Playboy founder Hugh Hefner ... the past half century. From his highly publicized lifestyle ... Hefner has played a leading role in reshaping America,s ... Steven Watts, professor of history in the College of ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Breast Cancer Coalition and celebrate fifteen,years of Education, ... The Pennsylvania,Breast Cancer Coalition (PBCC) Annual Conference ... the Harrisburg Hilton & Towers from 7 a.m. ... of education, advocacy, and research., Pat Halpin-Murphy, ...
... 2008, CHENGDU, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ ... TYNP), a manufacturer and,supplier of modernized traditional ... announced that the Company has received approval ... (SFDA) to produce Laonian,Kechuan Tablets in the ...
... prominent international awards from the European Society of Cardiology ... treat conditions of the heart. , Professor John Martin, ... Medicine and British Heart Foundation Professor of Cardiovascular Science, ... other holder of this medal in the UK is ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009 2Health News:Playboy founder embodies American Dream; changes American culture 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 3Health News:UCL academics awarded prestigious prizes for work on the heart 2
(Date:4/20/2015)... April 20, 2015  Fewer blockbusters drugs are expected ... of opportunities for generic companies in Asia ... are looking beyond the patent cliff to focus on ... Certain established generic manufacturers are restructuring their business models ... molecules, although the impact of these efforts will take ...
(Date:4/20/2015)... PORTLAND, Ore. , April 20, 2015 /PRNewswire/ ... the National Academy of Sciences (PNAS) demonstrates ... & Science University,s Casey Eye Institute ... causes of blindness. Optical coherence tomography (OCT) angiography ... management of these diseases. OHSU researchers ...
(Date:4/20/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... the Phase 1 study of MM-302, a novel ... The results were presented today by Patricia LoRusso, ... at the 2015 American Association for Cancer Research ... Data described the safety and promising ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5
... Life Pharmaceuticals, soon to be changed from Hybrid Fuels, ... that it is in development of an online pharmacy ... the Company to sell and service internationally while building ... part of the online pharmacy, the Company will provide ...
... CARDIFF, Calif., March 7, 2012 NeuroPerspective ... area, has released its March issue, which reviews the field ... "There are those that claim that ADHD is a fabrication, ... psychotropic web in the name of corporate profits. Even well-regarded ...
Cached Medicine Technology:HRID Launches Plan to Expand Into World-Wide Market 2ADHD Therapeutics Reviewed by NeuroPerspective 2ADHD Therapeutics Reviewed by NeuroPerspective 3
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... System from KUBTEC is a dual capability system ... dimensional representation of the specimen under test. While ... X-ray images, the micro focus source also allows ... in standard 2D images. The 100 mm x ...
... The Duet Logic G|2 Provides Microsoft ... and reporting for clinics where logic, ... Medtronic diagnostic system is designed with ... physicians to combine different diagnostic tools ...
... experience in the field of Urodynamics, Albyn Medical ... Our new chair is manufactured from the highest ... studies can be improved considerably if the patient ... and this aspect was given a high priority ...
Medicine Products: